Clinical Trial Update: Feasibility of Semaglutide in Advanced Lung Disease [Phase 1, Phase 2]

View source ↗

Summary

Feasibility study of the GLP-1 agonist semaglutide for patients with obesity and advanced lung diseases, spanning Phase 1 and Phase 2, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Interstitial Lung Disease
• Obesity
• Pulmonary Hypertension
• Pulmonary Sarcoidosis

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: University of Pennsylvania | Conditions: Obesity, Interstitial Lung Disease | Phase 1, Phase 2 | Status: RECRUITING